Targeting the HIV-protease in AIDS therapy: A current clinical perspective

Biochimica et Biophysica Acta - Protein Structure and Molecular Enzymology

Volumn 1477, Issue 1-2, 2000, Pages 189-214

  Tomasselli, Alfredo G ^a   Heinrikson, Robert L ^a  

^a PFIZER INC   (United States)

Author keywords

AIDS; Computer assisted drug design; High throughput screening; Highly active antiretroviral therapy; HIV; Protease; Protease inhibitor; Viral resistance

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; INDINAVIR; LAMIVUDINE; NELFINAVIR; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; COMPUTER ANALYSIS; DRUG DESIGN; DRUG EFFICACY; ENZYME STRUCTURE, FUNCTION AND VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; BINDING SITES; CARBAMATES; CLINICAL TRIALS; COMPUTER-AIDED DESIGN; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; NELFINAVIR; OLIGOPEPTIDES; PYRIDINES; PYRONES; RANDOMIZED CONTROLLED TRIALS; RITONAVIR; SAQUINAVIR; SULFONAMIDES;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0034615554     PISSN: 01674838     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-4838(99)00273-3     Document Type: Review

References (90)

1. Neurath H. The versatility of proteolytic enzymes. J. Cell. Biol. 32:1986;1-15.
2. Muesling M.A., Smith D.H., Cabradilla C.D., Benton C.V., Lasky L.A., Capon D.J. Nucleic acid structure and expression of the human AIDS/lymphadenopathy retrovirus. Nature. 313:1985;450-458.
3. Kohl N.E., Emini E.A., Schleif W.A., Davis L.J., Heimbach J.C., Dixon R.A.F., Scolnick E.M., Sigal I.S. Active protease is required for viral infectivity. Proc. Natl. Acad. Sci. USA. 85:1988;4686-4690.
4. A.G. Tomasselli, S. Thaisrivongs, R.L. Heinrikson. HIV-Pr inhibitors: novel chemotherapeutic agents for AIDS treatment, in: E. De Clercq (Ed.), Advances in Antiviral Drug Design, 1996, pp. 173-228, JAI Press Inc., Greenwich (CT), USA, London (England).
5. Vacca J.P., Condra J.H. Clinically effective HIV-1 protease inhibitors. Drug Discov. Today. 2:1997;261-272.
6. Wlodawer A., Vondrasek J. Inhibitors of HIV-1 protease: a major success of structure assisted drug design. Annu. Rev. Biophys. Biomol. Struct. 27:1998;249-284.
7. Gago F. Targeting HIV-1 protease: from peptidomimetics to non-peptide inhibitors. IDrugs. 2:1999;309-320.
8. Holtzer C.D., Roland M. The use of combination antiretroviral therapy in HIV-infected patients. Ann. Pharmacother. 33:1999;198-209.
9. Tomasselli A.G., Howe W.J., Sawyer T.K., Wlodawer A., Heinrikson R.L. The complexities of AIDS: an assessment of the HIV-Pr as a therapeutic target. Chim. Oggi. 5:1991;6-27.
10. Davies D.R. The structure and function of the aspartic proteinases. Annu. Rev. Biophys. Biophys. Chem. 19:1990;189-215.
11. Pearl L.H., Taylor W.R. A structural model for the retroviral proteases. Nature. 329:1987;351-354.
12. Debouck C., Gorniak J.G., Strickler J.E., Meek T.D., Metcalf B.W., Rosenberg M. HIV-Pr expressed in E. coli exhibits autoprocessing and specific maturation of the Gag precursor. Proc. Natl. Acad. Sci. USA. 84:1987;8903-8906.
13. Darke P.L., Leu C.-T., Davis L.J., Heimbach J.C., Diehl R.E., Hil W.S., Dixon R.A.F., Sigal I.S. HIV-1 protease: bacterial expression and characterization. J. Biol. Chem. 264:1989;2307-2312.
14. Tomasselli A.G., Olsen M.K., Hui J.O., Sawyer T.K., Heinrikson R.L., Tomich C.-S.C. Substrate analog inhibition and active site titration of purified recombinant HIV-1 protease. Biochemistry. 29:1990;264-269.
15. Hui J.O., Tomasselli A.G., Reardon I.M., Lull J.M., Brunner D.P., Tomich C.-S., Heinrikson R.L. Large scale purification and refolding of HIV-1 protease from Escherichia coli inclusion bodies. J. Protein Chem. 12:1993;323-327.
16. Tomasselli A.G., Sarcich J.L., Barrett L.J., Reardon I.M., Howe W.J., Evans D.B., Sharma S.K., Heinrikson R.L. HIV-1 reverse transcriptase and ribonuclease H as substrates of the viral protease. Protein Sci. 2:1993;2167-2176.
17. Tomasselli A.G., Heinrikson R.L. Specificity of HIV-1 proteases: an analysis of non-viral protein substrates. Methods Enzymol. Retroviral Proteases. 241:1994;279-301.
18. Poorman R.A., Tomasselli A.G., Heinrikson R.L., Kezdy F.J. A cumulative specificity model for HIV-1 and HIV-2 proteases inferred from statistical analysis of an extended substrate data base. J. Biol. Chem. 266:1991;14554-14561.
19. Zhang C.-T., Chou K.-C. An alternate-subsite-coupled model for predicting HIV-Pr cleavage sites in proteins. Protein Eng. 7:1994;65-73.
20. Tomasselli A.G., Hui J.O., Sawyer T.K., Staples D.J., Fitzgerald D.J., Chaudhary V.K., Pastan I., Heinrikson R.L. Interdomain hydrolysis of a truncated pseudomonas exotoxin by the human immunodeficiency virus-1 protease. J. Biol. Chem. 265:1990;408-413.
21. Thanki N., Rao J.K.M., Foundling S.I., Howe W.J., Moon J.B., Hui J.O., Tomasselli A.G., Heinrikson R.L., Thaisrivongs S., Wlodawer A. Crystal structure of a complex of HIV-1 protease with a dihydroxyethylene-containing inhibitor: comparisons with molecular modeling. Protein Sci. 1:1992;1061-1072.
22. Jaskolski M., Tomasselli A.G., Sawyer T.K., Staples D.G., Heinrikson R.L., Schneider J., Kent S.B.H., Wlodawer A. Structure at 0.25 nm resolution of chemically synthesized HIV-1 protease complexed with a hydroxyethylene-based inhibitor. Biochemistry. 30:1991;1600-1609.
23. 18O isotope exchange. Biochemistry. 30:1991;8441-8453.
24. Hyland L.J., Tomaszek T.A., Meek T.D. HIV-1 protease. 2. Use of pH rate studies and solvent kinetic isotope effects to elucidate details of the chemical mechanism. Biochemistry. 30:1991;8454-8463.
25. Weber T. Comparison of the crystal structures and intersubunit interactions of human immunodeficiency and Rous sarcoma virus proteases. J. Biol. Chem. 265:1990;10492-10496.
26. Zhang Z.-Y., Poorman R.A., Maggiora L.L., Heinrikson R.L., Kezdy F.J. Dissociative inhibition of dimeric enzymes: kinetic characterization of HIV-1 protease by its COOH-terminal tetrapeptide. J. Biol. Chem. 266:1991;15591-15594.
27. Cheng Y.-.S.E., Yin F.H., Foundling S., Blomstrom D., Kettner C.A. Stability and activity of the HIV-Pr: comparison of the natural dimer with a homologous, single chain tethered dimer. Proc. Natl. Acad. Sci. USA. 87:1990;9660-9664.
28. DiIanni C.L., Davis L.J., Holloway M.K., Herber W.K., Darke P.L., Kohl N.E., Dixon R.A.F. Characterization of an active single polypeptide form of the HIV-1 protease. J. Biol. Chem. 265:1990;17348-17354.
29. Gustchina A., Sansom C., Prevost M., Richelle J., Wodak S.Y., Wlodawer A., Weber I.T. Energy calculations and analysis of HIV-1 protease+inhibitor crystal structures. Protein Eng. 7:1994;309-317.
30. Munoz A., Xu J. Models for the incubation of AIDS and variation according to age and period. Stat. Med. 15:1996;2459-2473.
31. Phair J., Jacobson L., Detels R., Rinaldo C., Saah A., Schrager L., et al. Acquired immunodeficiency syndrome occurring within 5 years of infection with human immunodeficiency virus type-1: the Multicenter Cohort Study. J. Acquired Immune Defic. Syndr. 5:1992;490-496.
32. Sheppard H.W., Lang W., Ascher M.S., Vittinghoff E., Winkelstein W. The characterization of non-progressors: long-term HIV-1 infection with stables CD4+ T-cell levels. AIDS. 7:1993;1159-1166.
33. Mellors J.W., Munoz A., Giorgi J.V., Margolick J.B., Tassoni C.J., Gupta P., Kingsley L.A., Todd J.A., Saah A.J., Detels L., Phair J.P., Rinaldo C.R. Plasma viral load and CD4+ counts as prognostic markers of HIV-1 infection. Ann. Intern. Med. 126:1997;946-954.
34. Marschner I.C., Collier A.C., Coombs R.W., D'Aquila R.T., DeGruttola V., Fischl M.A., Hammer C.M., Hughes M.D., Johnson V.A., Katzenstein D.A., Richman D.D., Smeaton L.M., Spector S.A., Saag M.S. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J. Infect. Dis. 177:1998;40-47.
35. Carpenter C.J., Fischl M.A., Hammer S.M., Hirsch M.S., Jacobsen D.M., Katzeinstein D.A., et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA panel. J. Am. Med. Assoc. 280:1998;78-86.
36. Department of Health and Human Services and Henry J. Kaiser Family Foundation, Guidelines for the Use of Antiretroviral Agents in HIV Infected Adults and Adolescents. Federal Register, June 17, 1998, pp. 1-50.
37. Tomasselli A.G., Hui J.O., Sawyer T.K., Staples D.J., Bannow C., Reardon I.M., Howe W.J., DeCamp D.L., Craik C.S., Heinrikson R.L. Specificity and inhibition of proteases from HIV-1 and HIV-2. J. Biol. Chem. 265:1990;14675-14683.
38. A.G. Tomasselli, J.O. Hui, T.K. Sawyer, S. Thaisrivongs, J. Hester, R.L. Heinrikson, The evaluation of non-viral substrates of the HIV-Pr as leads in the design of inhibitors for AIDS therapy, in: B. Dunn (Ed.), Structure and Function of the Aspartic Proteinases: Genetics, Structure and Mechanism. Advances in Experimental Medicine and Biology, Vol. 306, Plenum Press, New York, 1991, pp. 473-486.
39. Meek T.D., Lambert D.M., Dreyer G.B., Carr T.J., Tomaszek T.J. Jr., Moore M.L., Strickler J.E., Debouck C., Hyland L.J., Matthews T.J., Metcalf B.W., Petteway S.R. Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues. Nature. 343:1990;90-92.
40. McQuade T.J., Tomasselli A.G., Liu L., Karacostas V., Moss B., Sawyer T.K., Heinrikson R.L., Tarpley W.G. A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation. Science. 247:1990;454-456.
41. Ashorn P., McQuade T.J., Thaisrivongs S., Tomasselli A.G., Tarpley W.G., Moss B. An inhibitor of the protease blocks maturation of human and simian immunodeficency viruses and spread of infection. Proc. Natl. Acad. Sci. USA. 87:1990;7472-7476.
42. Thaisrivongs S., Tomasselli A.G., Moon J.B., Hui J.O., McQuade T.J., Turner S.R., Strohbach J.W., Howe W.J., Tarpley W.G., Heinrikson R.L. Inhibitors of the HIV-Pr: design and modeling of a compound containing a dihydroxyethylene isostere insert with high binding affinity and effective antiviral activity. J. Med. Chem. 34:1991;2344-2356.
43. Martin L.N., Soike K.F., Murphey-Corb M., Bohm R.P., Roberts E.D., Kakuk T.J., Thaisrivongs S., Vidmar T.J., Ruwart M.J., Davio S.R., Tarpley W.G. Effects of U-75875, a peptidomimetic inhibitor of retroviral proteases, on simian immunodeficiency virus infection in rhesus monkeys. Antimicrob. Antiviral Chemother. 38:1994;1277-1283.
44. Tomasselli A.G., Bannow C.A., Deibel M.R. Jr., Hui J.O., Zurcher-Neely H., Reardon I.M., Smith C.W., Heinrikson R.L. Chemical synthesis of a biotinylated derivative of the simian immunodeficiency virus protease: purification by avidin affinity chromatography and autocatalytic activation. J. Biol. Chem. 267:1992;10232-10237.
45. Roberts N.A., Martin J.A., Kinchington D., Broadhurst A.V., Craig J.C., Duncan I.B., Galpin S.A., Handa B.K., Kay J., Krohn A., Lambert R.W., Merrett J.H., Mills J.S., Parkes K.E.B., Redshaw S., Ritchie A.J., Taylor D.L., Thomas G.J., Machin P.J. Rational design of peptide-based HIV proteinase inhibitors. Science. 248:1990;358-361.
46. Martin J.A. Recent advances in the design of HIV proteinase inhibitors. Antiviral Res. 17:1992;265-278.
47. Collier A.C., Coombs R.W., Schoenfeld D.A., Bassett R.L., Timpone J., Baruch A., et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine and zalcitabine. New Engl. J. Med. 334:1996;1011-1017.
48. J. Lilezari, R. Haubrich, H.U. Burger, D. Beattie, L. Donatacci, M.P. Salgo, et al., Improved survival and decreased progression of HIV in patients treated with sequinavir plus Hivid (abstract). The XI Conference on AIDS, Vancouver, Canada, July 7-12, 1996.
49. th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 1-5, 1998.
50. Erickson J.W., Neidhart D.J., Van Drie J., Kempf D.J., Wang X.C., Norbeck D.W., Plattner J.J., Rittenhouse J.W., Turon M., Wideburg N., Kohlbrenner W.E., Simmer R., Helfrich R., Paul D.A., Knigge M. Design, activity, and 0.28 nm crystal structure of a C2 symmetric inhibitor complexed to the HIV-1 protease. Science. 249:1990;527-533.
51. Hosur M.W., Bhat T.N., Kempf D.J., Baldwin E.T., Liu B., Gulnik S., Wideburg N.E., Norbeck D.W., Appelt K., Erickson J.W. Influence of stereochemistry on activity and binding modes for C2 symmetry-based diol inhibitors of HIV-1 protease. J. Am. Chem. Soc. 116:1994;847-855.
52. D.W. Cameron, M. Heah-Chiozzi, S. Danner, C. Cohen, S. Kravcik, C. Maurath, E. Sun,D. Henry, R. Rode, A. Potthoff, J. Leonard, for the Advanced HIV Ritonavir Study Group, Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease, Lancet 351 (1998) 543-549.
53. Lyle T.A., Wiscount C.M., Guare J.P., Thompson W.T., Anderson P.S., Darke P.L., Zugay J.A., Emini E.A., Schleif W.A., Quintero J.C., Dixon R.A.F., Sigal I.S., Huff J.R. Benzocycloalkyl amines as novel C-termini for HIV-Pr inhibitors. J. Med. Chem. 34:1991;1228-1230.
54. Vacca J.P., Dorsey B.D., Schleif W.A., Levin R.B., McDaniel S.L., Darke P.L., Zugay J., Quintero J.C., Blahy O.M., Roth E., Sardana V.V., Schlabach A.J., Graham P.I., Condra J.H., Gotlib L., Holloway M.K., Lin J., Chen I.-W., Vastag K., Ostovic D., Anderson P.S., Emini E.A., Huff J.R. L-735, 524: an orally bioavailable HIV-1 protease inhibitor. Proc. Natl. Acad. Sci. USA. 91:1994;4096-4100.
55. Hammer S.M., Squires K.E., Hughes M.D., Grimes M.J., Demeter L.M., Currier J.S., et al. A controlled trial of two nucleosides analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimiter or less. New Engl. J. Med. 337:1997;725-733.
56. P.K. Tomich, M.J. Bohanon, J.C. Lynn, J.E. McGee, S. Thaisrivongs, J.W. Strohbach, S.R. Turner, C.P.Yang, L.L. Skaletzky, F.J. Schwende, G.M. Howard, G.E. Padbury, L.N. Toth, M.J. Ruwart, K.F. Wilkinson, R.D. Rush, A.M. Mulichak, K.D. Watenpaugh, Discovery and properties of small organic molecule inhibiting HIV-1 protease, Keystone Symposium on Structural and Molecular Biology of Protease Function and Inhibition, Santa Fe, NM, March 5-12, 1994.
57. K.D. Watenpaugh, A.M. Mulichak, S.R. Turner, J.W. Strohbach, C.P. Yang, S. Thaisrivongs, M.J. Bohanon, J.C. Lynn, P.K. Tomich, Collaborative structure-based design of small organic molecules as inhibitors of HIV-Prs, Keystone Symposium on Structural and Molecular Biology of Protease Function and Inhibition, Santa Fe, NM, March 5-12, 1994.
58. Thaisrivongs S., Skulnick H.I., Turner S.R., Strohbach J.W., Tommasi R.A., Johnson P.D., Aristoff P.A., Judge T.M., et al. Structure-based design of HIV-Pr inhibitors: sulfonamide-containing 5,6-dihydro-4-hydroxy-2-pyrones as non-peptidic inhibitors. J. Med. Chem. 39:1996;4349-4353.
59. Mildner A.M., Rothrock D.J., Leone J.W., Bannow C.A., Lull J.M., Reardon I.M., Sarcich J.L., Howe W.J., Tomich C-S.C., Smith C.W., Heinrikson R.L., Tomasselli A.G. The HIV-Pr as enzyme and substrate: mutagenesis of autolysis sites and generation of a stable mutant with retained kinetic properties. Biochemistry. 33:1994;9405-9413.
60. Koeplinger K.K., Zhao Z., Peterson T., Leone J.W., Schwende F.S., Heinrikson R.L., Tomasselli A.G. Activated sulfonamides are cleaved by glutathione S-transferases. Drug Metab. Dispos. 27:1999;986-991.
61. Zhao Z., Koeplinger K.A., Peterson T., Conradi R.A., Burton P.S., Suarato A., Heinrikson R.L., Tomasselli A.G. Mechanism, structure-activity studies and potential applications of glutathione S-transferase catalyzed cleavage of sulfonamides. Drug Metab. Dispos. 27:1999;992-998.
62. B. Larder, S. Bloor, K. Hertogs, C. Van Den Einde, W. DeCian, Y. Wang, W. Freimuth. Tipranavir is active against a large selection of highly protease inhibitor-resistant HIV-1 clinical samples (abstract), 3rd International Workshop on HIV Drug Resistance and Treatment Strategies, San Diego, CA, 1999.
63. Lam P.Y.S., Jadhav P.K., Eyermann C.J., Hodge C.N., Ru Y., Bacheler L.T., Meek J.L., Otto M.J., Rayner M.M., Wong Y.N., Chang C.W., Weber P.C., Jackson D.A., Sharpe T.R., Erickson-Vitanen S. Rational design of potent, nonpeptide cyclic ureas as HIV-Pr inhibitors. Science. 263:1994;380-383.
64. DeLucca G.V., Erickson-Vitanen S., Lam P.Y.S. Cyclic HIV-Pr inhibitors capable of displacing the active site water molecule. Drug Discov. Today. 2:1997;6-8.
65. Perry C.M., Benfield P. Nelfinavir. Drugs. 54:1997;81-87.
66. B. Clendenium, B. Quart, M. Anderson, M. Knowles, Y. Chang, Analysis of long-term virologic data from Viracept 511 protocol using 3 HIV-RNA assays (abstract), 5th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 1-5, 1998.
67. M. Saag, M. Knowles, Y. Chang, S. Chapman, B. Clendenium, for the Viracept Cooperative Study Group. Durable effect of Viracept in triple combination therapy (abstract) 37th ICAAC, Toronto, Canada, September 28-October 1, 1997.
68. N. Clumck for the AVANTI study group. AVANTI 3. A randomized, double-blind, comparative trial to evaluate the efficacy, safety and tolerance of AZT/3TC vs. AZT/3TC/nelfinavir in antiretroviral naive patients (abstract), 5th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 1-5, 1998.
69. Jacobsen H., Kasargil K., Craig J.C., Krohn A., Duncan I.B., Mous J. Characterization of human immunodeficiency virus type1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. Virology. 206:1995;527-534.
70. Noble S., Foulds D. Saquinavir: a review of its pharmacology and clinical potential in the management of HIV infection. Drugs. 52:1996;93-112.
71. Shapiro J.M., Winters M.A., Lawrence J., Merigan T.C. Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations. AIDS. 13:1999;359-365.
72. Vaillancourt M., Irlbeck D., Smith T., Coombs R.W., Swanstrom R. The HIV type 1 protease inhibitor sequinavir can select for multiple mutations that confer increasing resistance. AIDS Res. Hum. Retroviruses. 15:1999;355-363.
73. Molla X., Korneyeva M., Gao Q., Vasavanonda S., Schipper P.J., Mo H., Markovitz M., Chernyavskiy T., Niu P., Lyons N., et al. Ordered accumulation of mutations in HIV-Pr confers resistance to ritonavir. Nat. Med. 2:1996;760-766.
74. Condra J.H., Schleif W.A., Blahy O.M., Danovich R.M., Gabrielski L.J., Gaham D.J., Laird D., et al. Genetic correlates of an in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J. Virol. 70:1996;8270-8276.
75. Patick A.K., Duran M., Cao Y. Genotypic analysis of HIV-1 variants isolated from patients treated with the protease inhibitor nelfinavir, alone or in combination with d4T or AZT and 3TC [abstract], 4th Conference on Retroviruses and Opportunistic Infections. Antimicrob. Agents Chemother. 40:1996;292-297.
76. A.K. Patick, M. Duran, Y. Cao, et al., HIV-1 variants isolated from patient treated with the protease inhibitor nelfinavir are not cross-resistant to other protease inhibitors (abstract), AIDS 10, Suppl. 2 (1996) OP9.2.
77. Mocroft X., Vella S., Benfield T.L., Chiesi A., Miller V., Gargalianos P., d'Arminio Monforte A. Changing patterns of mortality accrross Europe in patients infected with HIV-1. Lancet. 352:1998;1725-1730.
78. Palella F.J., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., Aschman D.J., Holmberg S.D. Declining mortality among patients with advanced human immunodeficiency virus infection and the HIV Outpatient Study Investigators. New Engl. J. Med. 338:1998;853-860.
79. Jacobson M.A., French M. Altered natural history of AIDS-related opportunistic infections in the era of potent combination antiretroviral therapy. AIDS. 12:(Suppl. A):1998;S157-S163.
80. Powderly W.G., Landay A., Lederman M.M. Recovery of the immune system with antiretroviral therapy. The end of opportunism? J. Am. Med. Assoc. 280:1998;72-77.
81. Stephenson J. HIV researchers air new findings. J. Am. Med. Assoc. 281:1999;883-885.
82. Boucher C.A.B. HIV drug resistance tests are here to stay. Curr. Opin. Infect. Dis. 12:1999;27-32.
83. Katzenstein D.A. The regulation of HIV therapy to prevent resistance development. Curr. Opin. Anti-Infect. Invest. Drugs. 1:1999;150-154.
84. Kaufmann G.R., Cooper D.A. Effect of protease inhibitors on body composition, lipid and carbohydrate metabolism in HIV-1 infected subjects. Curr. Opin Anti-Infect. Invest. Drugs. 1:1999;166-170.
85. Martinez E., Gatell J.M. Metabolic abnormalities and body fat redistribution in HIV-1 infected patients: the lipodystrophy syndrome. Curr. Opin. Infect. Dis. 12:1999;13-19.
86. Carr A., Samaras K., Burton S., Law M., Freund J., Chisholm D.J., Cooper D.A. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV-Pr inhibitors. AIDS. 12:1998;F51-F58.
87. Carr A., Samaras K., Thoristottir A., Kaufman G., Chisholm D.J., Cooper D.A. Natural history, diagnosis and prediction of HIV-Pr inhibitor-associated lipodystrophy, hyperlipidaemia and diabetis mellitus. Lancet. 253:1999;2093-2099.
88. Pantaleo G., Perrin L. Can HIV be eradicated? AIDS. 12:(Suppl. A):1998;175-180.
89. Blankson J., Persuad D., Siliciano R.F. Latent reservoir for HIV-1. Curr. Opin. Infect. Dis. 12:1999;5-11.
90. Saag M.S., Kilby J.M. HIV and HAART: a time to cure, a time to kill. Nat. Med. 5:1999;609-611.